Jane H. Yoon is a partner in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Ms. Yoon represents corporate entities and their executives in connection with government and internal investigations into allegations of potential violations of the federal anti-kickback statute, health care fraud, the Food Drug & Cosmetic Act, HIPAA, and the False Claims Act. These matters range from conduct surrounding patient support/assistance programs, specialty pharmacy arrangements, clinical trials and investigator-initiated studies, promotional communications, and the full range of interactions between manufacturers, prescribers, third-party vendors, patients, and payers. Ms. Yoon also handles matters relating to allegations of billing fraud and Medicare risk adjustment practices under Medicare Advantage. A significant portion of her practice has been devoted to representing manufacturers, as well as senior principals, before the DOJ, HHS-OIG, various OIGs of federal agencies, and state attorneys general. Ms. Yoon also devotes substantial time assisting companies with undertaking proactive risk assessments and compliance program reviews, preparing for potential enforcement and/or qui tam activity, and provides day-to-day compliance counseling advice on patient assistance programs and promotional practices.
Prior to joining Paul Hastings, Ms. Yoon was an Assistant United States Attorney in the Health Care and Government Fraud Unit in the U.S. Attorney’s Office for the District of New Jersey for approximately seven years. Ms. Yoon led numerous investigations into health care fraud offenses, including investigations and prosecutions of fraud against the government and private health insurance plans, illegal kickback schemes, violations of the Federal Food, Drug & Cosmetic Act, False Claims Act cases, and the improper diversion of prescription drugs. She also prosecuted and tried several complex tax fraud offenses and cases involving fraud against various government agencies and private entities, and investigated and prosecuted the one of the first federal criminal cases involving compounding pharmacy fraud in the United States. An experienced trial attorney, Ms. Yoon recently served as trial counsel to a former Deutsche Bank trading desk supervisor in a month-long criminal LIBOR manipulation trial before the Chief Judge of the Southern District of New York.
Paul Hastings Recognized for International Pro Bono Excellence by Vance Center for International Justice
October 28, 2019
Paul Hastings Wins Law360 Life Sciences Practice Group of the Year
February 05, 2018
Paul Hastings Investigations and White Collar Defense Practice Named Most Impressive Investigations Practice by Leading Industry Publication Global Investigations Review
October 31, 2017
Paul Hastings Adds Former Assistant U.S. Attorney to Growing Investigations and White Collar Defense Practice
January 04, 2017
As Enforcement Against Hoarding and Price Gouging Escalates Amidst the COVID-19 Crisis, What Corporate Compliance Can Do
April 28, 2020
Compliance in the Era of COVID-19 – Where and How Life Sciences and Health Care Companies Should Focus in the Era of Social Distancing
April 22, 2020
Another Life Sciences Company Announces a Multi-Million Dollar Settlement in the U.S. Department of Justice’s Relentless Pursuit of Donations to Copay Assistance Charities
June 19, 2018
Against the Backdrop of a ‘National Emergency,’ Are Opioid Cos. Ready for the Enforcement Spotlight?
September 06, 2017
Against the Backdrop of a ‘National Emergency,’ Are Opioid Manufacturers Ready for the Enforcement Spotlight?
August 25, 2017
Recognized as Law360 Practice Group of the Year in Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360. The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product. The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
February 01, 2018